Display options
Share it on

Pharmacol Res Perspect. 2021 Aug;9(4):e00817. doi: 10.1002/prp2.817.

Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? Review of selected literature.

Pharmacology research & perspectives

Sylwester Drożdżal, Kacper Lechowicz, Bartosz Szostak, Jakub Rosik, Katarzyna Kotfis, Anna Machoy-Mokrzyńska, Monika Białecka, Kazimierz Ciechanowski, Barbara Gawrońska-Szklarz

Affiliations

  1. Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, Szczecin, Poland.
  2. Department of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University, Szczecin, Poland.
  3. Department of Physiology, Pomeranian Medical University, Szczecin, Poland.
  4. Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland.
  5. Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Szczecin, Poland.

PMID: 34310861 PMCID: PMC8313037 DOI: 10.1002/prp2.817

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely available drugs with anti-inflammatory and analgesic properties. Their mechanism of action is associated with the enzymes of the arachidonic acid cycle (cyclooxygenases: COX-1 and COX-2). The cyclooxygenase pathway results in the formation of prostanoids (prostaglandins [PGs], prostacyclins, and thromboxanes). It affects various structures of the human body, including the kidneys. Medical literature associates the usage of NSAIDs with acute kidney injury (AKI), tubulointerstitial nephritis (TIN), as well as nephrotic syndrome and chronic kidney disease (CKD). AKI associated with the chronic consumption of NSAIDs is mainly attributed to pharmacological polytherapy and the presence of cardiovascular or hepatic comorbidities. The pathomechanism of AKI and CKD is associated with inhibition of the biosynthesis of prostanoids involved in the maintenance of renal blood flow, especially PGE2 and PGI2. It is suggested that both COX isoforms play opposing roles in renal function, with natriuresis increased by COX-1 inhibition followed by a drop in a blood pressure, whereas COX-2 inhibition increases blood pressure and promotes sodium retention. TIN after NSAID use is potentially associated with glomerular basement membrane damage, reduction in pore size, and podocyte density. Therefore, nephrotic proteinuria and impairment of renal function may occur. The following article analyzes the association of NSAIDs with kidney disease based on available medical literature.

© 2021 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

Keywords: AKI; CKD; NSAIDs; nephrotoxicity

References

  1. J Am Soc Nephrol. 2015 Sep;26(9):2231-8 - PubMed
  2. Clin Ther. 2003 Jan;25(1):1-18 - PubMed
  3. J Pediatr Pharmacol Ther. 2020;25(7):606-616 - PubMed
  4. Hypertension. 2006 Aug;48(2):323-8 - PubMed
  5. Eur J Pediatr. 2021 Feb;180(2):655-661 - PubMed
  6. Nephron Clin Pract. 2012;120(4):c179-84 - PubMed
  7. BMC Nephrol. 2017 Aug 1;18(1):256 - PubMed
  8. Am J Kidney Dis. 2020 Oct;76(4):546-557 - PubMed
  9. JAMA Netw Open. 2020 Sep 1;3(9):e2016839 - PubMed
  10. J Clin Med. 2020 Sep 13;9(9): - PubMed
  11. South Med J. 1993 Dec;86(12):1421-4 - PubMed
  12. Int J Mol Sci. 2019 Aug 30;20(17): - PubMed
  13. Hypertension. 1997 Sep;30(3 Pt 2):664-6 - PubMed
  14. Clin Kidney J. 2017 Oct;10(5):688-697 - PubMed
  15. Lancet. 2012 Aug 25;380(9843):756-66 - PubMed
  16. Biomed Res Int. 2020 Sep 14;2020:9742754 - PubMed
  17. Curr Opin Nephrol Hypertens. 2020 Nov;29(6):671-680 - PubMed
  18. Physiol Rev. 1996 Apr;76(2):425-536 - PubMed
  19. J Clin Invest. 2002 Jul;110(1):61-9 - PubMed
  20. Am J Kidney Dis. 2020 Aug;76(2):184-193 - PubMed
  21. Kidney Int. 1994 Mar;45(3):650-8 - PubMed
  22. Circulation. 2007 Mar 27;115(12):1634-42 - PubMed
  23. Yakugaku Zasshi. 2020;140(7):943-947 - PubMed
  24. Am J Kidney Dis. 2020 Nov;76(5):742-743 - PubMed
  25. Ann Surg. 2020 Oct 14;: - PubMed
  26. Crit Care. 2013 Feb 04;17(1):204 - PubMed
  27. Musculoskeletal Care. 2020 Jun;18(2):134-139 - PubMed
  28. Am J Epidemiol. 2000 Mar 1;151(5):488-96 - PubMed
  29. J Cell Mol Med. 2009 Sep;13(9B):3753-63 - PubMed
  30. J Clin Invest. 2006 May;116(5):1391-9 - PubMed
  31. Am J Physiol Renal Physiol. 2003 Jan;284(1):F11-21 - PubMed
  32. Am J Kidney Dis. 2002 Jun;39(6):1313-7 - PubMed
  33. J Clin Med. 2020 May 04;9(5): - PubMed
  34. J Pharm Pharm Sci. 2013;16(5):821-47 - PubMed
  35. Ther Clin Risk Manag. 2018 Mar 23;14:595-599 - PubMed
  36. PLoS One. 2015 Sep 25;10(9):e0136508 - PubMed
  37. Am J Cardiol. 2010 Sep 15;106(6):873-84 - PubMed
  38. Clin Sci (Lond). 2013 Jun;124(11):685-94 - PubMed
  39. J Thorac Cardiovasc Surg. 2020 Sep;160(3):712-719 - PubMed
  40. Pharmaceuticals (Basel). 2010 Jul 21;3(7):2291-2321 - PubMed
  41. Clin J Am Soc Nephrol. 2019 Sep 6;14(9):1355-1362 - PubMed
  42. Kidney Int. 2015 Aug;88(2):396-403 - PubMed
  43. J Neurochem. 1990 Jul;55(1):1-15 - PubMed
  44. Hypertension. 2007 Mar;49(3):408-18 - PubMed

Publication Types